Icon (NASDAQ:ICLR) Issues Earnings Results, Beats Expectations By $0.01 EPS

Icon (NASDAQ:ICLR) issued its earnings results on Wednesday. The medical research company reported $2.56 earnings per share for the quarter, topping the consensus estimate of $2.55 by $0.01, FiscalAI reports. Icon had a net margin of 3.99% and a return on equity of 8.04%. The company had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2 billion. During the same period in the prior year, the business posted $3.26 earnings per share. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year.

Icon Price Performance

Shares of NASDAQ ICLR traded down $2.11 during trading on Friday, reaching $163.42. The company had a trading volume of 102,304 shares, compared to its average volume of 1,416,212. The company has a current ratio of 1.14, a quick ratio of 1.14 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $12.51 billion, a PE ratio of 38.54, a price-to-earnings-growth ratio of 8.75 and a beta of 1.22. Icon has a twelve month low of $66.57 and a twelve month high of $203.91. The stock has a 50-day moving average price of $155.77 and a two-hundred day moving average price of $135.43.

Analysts Set New Price Targets

Several equities analysts recently weighed in on ICLR shares. Zacks Research raised Icon from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Barclays boosted their target price on Icon from $160.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Thursday, June 25th. JPMorgan Chase & Co. upped their target price on Icon from $130.00 to $155.00 and gave the company a “neutral” rating in a report on Thursday, June 25th. Mizuho lifted their price target on Icon from $180.00 to $190.00 and gave the stock an “outperform” rating in a research note on Friday, June 26th. Finally, Piper Sandler lowered shares of Icon to a “neutral” rating in a research report on Thursday, May 28th. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $169.40.

Trending Headlines about Icon

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Truist reaffirmed its “Buy” rating and raised its price target to $209 from $207, implying substantial potential upside from recent trading levels. Benzinga analyst rating report
• Positive Sentiment: Icon’s second-quarter discussion highlighted a strong surge in bookings and net book-to-bill, suggesting healthy demand and improved future revenue visibility. Q2 2026 earnings call highlights
• Positive Sentiment: The company announced a multi-year collaboration with Anthropic to expand artificial intelligence applications across clinical trials, potentially improving trial efficiency and supporting longer-term growth. ICON Anthropic collaboration
• Neutral Sentiment: Zacks upgraded Icon from “Strong Sell” to “Hold,” a less-negative assessment but not a bullish recommendation. Zacks rating update
• Negative Sentiment: Second-quarter EPS of $2.56 declined from $3.26 a year earlier and was described by Zacks as narrowly missing its $2.57 consensus estimate. Management also pointed to margin pressures, which may be limiting the stock’s reaction despite solid bookings. Icon Q2 earnings estimate report

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ICLR. WINTON GROUP Ltd acquired a new stake in shares of Icon during the 2nd quarter worth about $254,000. Daiwa Securities Group Inc. raised its position in shares of Icon by 19.3% in the second quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company’s stock valued at $4,094,000 after buying an additional 4,546 shares during the last quarter. Frontier Capital Management Co. LLC lifted its stake in shares of Icon by 97.6% during the second quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company’s stock valued at $10,379,000 after buying an additional 35,253 shares during the period. Peapack Gladstone Financial Corp acquired a new stake in Icon during the second quarter worth approximately $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Icon by 58.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock worth $113,000 after acquiring an additional 289 shares during the last quarter. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.